| Market Cap | 5.88K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -37.19M | Forward P/E | 0.00 | EPS next Y | - | 50D Avg Chg | -98.00% |
| Sales | 1.91M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -100.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | 2.70 | Quick Ratio | 1.12 | Shares Outstanding | 58.78M | 52W Low Chg | - |
| Insider Own | 6.22% | ROA | -57.59% | Shares Float | 54.11M | Beta | 1.60 |
| Inst Own | 1.25% | ROE | -525.78% | Shares Shorted/Prior | 1.64M/2.97M | Price | 0.00010 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 96,883 | Target Price | 3.08 |
| Oper. Margin | -2,958.87% | Earnings Date | Mar 8 | Volume | 30,268 | Change | -85.71% |
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Walker Paul Edward | 10% Owner 10% Owner | May 24 | Sell | 0.07 | 10,376,936 | 726,386 | 05/26/22 | |
| Sonsini Peter W. | 10% Owner 10% Owner | May 24 | Sell | 0.07 | 10,376,936 | 726,386 | 05/26/22 | |
| SANDELL SCOTT D | 10% Owner 10% Owner | May 24 | Sell | 0.07 | 10,376,936 | 726,386 | 05/26/22 | |
| New Enterprise Associates 16,... | 10% Owner 10% Owner | May 24 | Sell | 0.07 | 10,376,936 | 726,386 | 05/26/22 | |
| Makhzoumi Mohamad | 10% Owner 10% Owner | May 24 | Sell | 0.07 | 10,376,936 | 726,386 | 05/26/22 | |
| Florence Anthony A. Jr. | 10% Owner 10% Owner | May 24 | Sell | 0.07 | 10,376,936 | 726,386 | 05/26/22 | |
| Chang Carmen | 10% Owner 10% Owner | May 24 | Sell | 0.07 | 10,376,936 | 726,386 | 05/26/22 | |
| Behbahani Ali | Director Director | May 24 | Sell | 0.07 | 10,376,936 | 726,386 | 05/26/22 | |
| BASKETT FOREST | 10% Owner 10% Owner | May 24 | Sell | 0.07 | 10,376,936 | 726,386 | 05/26/22 | |
| Flechtner Jessica Baker | Chief Scientific Off.. Chief Scientific Officer | Apr 04 | Sell | 1.25 | 1,212 | 1,515 | 96,193 | 04/05/22 |
| Duvall Diantha | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Apr 04 | Sell | 1.25 | 963 | 1,204 | 91,775 | 04/05/22 |
| Davis Thomas Andrew | CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER | Apr 04 | Sell | 1.25 | 1,091 | 1,364 | 68,330 | 04/05/22 |
| Clark William D | President and CEO President and CEO | Apr 04 | Sell | 1.25 | 3,924 | 4,905 | 369,487 | 04/05/22 |
| Aakalu Girish N | CHIEF BUSINESS OFFIC.. CHIEF BUSINESS OFFICER | Apr 04 | Sell | 1.25 | 963 | 1,204 | 74,459 | 04/05/22 |
| Aakalu Girish N | CHIEF BUSINESS OFFIC.. CHIEF BUSINESS OFFICER | Mar 15 | Sell | 1.1 | 2,397 | 2,637 | 75,422 | 03/17/22 |